ReviewMovement disorders : official journal of the Movement Disorder Society2016
A review of disease progression models of Parkinson's disease and applications in clinical trials.
Review in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Rewiring Lipid Metabolism: PINK1 as a Central Regulator of Mitochondrial Homeostasis in Parkinson's Disease.International journal of molecular sciences · 2026Review
- Prediction of Motor Symptom Progression of Parkinson's Disease Through Multimodal Imaging-Based Machine Learning.Journal of imaging informatics in medicine · 2026Article
- Evaluating multivariable prediction models for Parkinson's disease prognosis: a scoping review protocol.BMJ open · 2025Article
- Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.Neurology · 2025Observational
- Balancing practicality and complexity in neuroimaging models of Parkinson's disease progression.NPJ Parkinson's disease · 2025Article
- Identifying brain degeneration patterns in early-stage Parkinson's disease: a multimodal MRI study.NPJ Parkinson's disease · 2025Article
- Development of a Cohort Analytics Tool for Monitoring Progression Patterns in Cardiovascular Diseases: Advanced Stochastic Modeling Approach.JMIR medical informatics · 2024Article
- Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Deep Learning-Assisted Gait Parameter Assessment for Neurodegenerative Diseases: Model Development and Validation.Journal of medical Internet research · 2023Article
- Article
- Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population.NPJ Parkinson's disease · 2023Article
- Gait Characteristics Analyzed with Smartphone IMU Sensors in Subjects with Parkinsonism under the Conditions of "Dry" Immersion.Sensors (Basel, Switzerland) · 2022Article
- Digital Phenotyping in Clinical Neurology.Seminars in neurology · 2022Article
- Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Preventing Parkinson's Disease: An Environmental Agenda.Journal of Parkinson's disease · 2022Review
- Quantifying Parkinson's disease motor severity under uncertainty using MDS-UPDRS videos.Medical image analysis · 2021Article
- Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology.Genes · 2021Review
- Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.Neurology · 2021Article
- Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study.Journal of market access & health policy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Quantitative disease progression models for neurodegenerative disorders are gaining recognition as important tools for drug development and evaluation. In Parkinson's disease (PD), several models have described longitudinal changes in the Unified Parkinson's Disease Rating Scale (UPDRS), one of the most utilized outcome measures for PD trials assessing disease progression. We conducted a literature review to examine the methods and applications of quantitative disease progression modeling for PD using a combination of key words including "Parkinson disease," "progression," and "model." For this review, we focused on models of PD progression quantifying changes in the total UPDRS scores against time. Four different models reporting equations and parameters have been published using linear and nonlinear functions. The reasons for constructing disease progression models of PD thus far have been to quantify disease trajectories of PD patients in active and inactive treatment arms of clinical trials, to quantify and discern symptomatic and disease-modifying treatment effects, and to demonstrate how model-based methods may be used to design clinical trials. The historical lack of efficiency of PD clinical trials begs for model-based simulations in planning for studies that result in more informative conclusions, particularly around disease modification. © 2016 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.